Arcellx, Inc.

Subdomain, LLC

Human Genome Sciences, Inc.

Zyngenia, Inc.

Teva Pharmaceutical Industries Limited

Zygenia, Inc.

David William Lafleur

David M Hilbert

Viktor Roschke

Peter Kiener

Craig A Rosen

Steven M Ruben

Jian Ni

Paul A Moore

Henrik S Olsen

Reinhard Ebner

Paul E Young

Yanggu Shi

Gregory A Endress

Laurie A Brewer

Kimberly A Florence

Jeffrey S Swers

Kenneth C Carter

Guo-Liang Yu

Yi Li

Ying-Fei Wei

Daniel R Soppet

Ann MeeJin Ferrie

John M Greene

Jing-Shan Hu

Ping Feng

Hla Kyaw

Zhizhen Zeng

Carrie L Fischer

Justin Edwards

Patrick J Dillon

William A Haseltine

Roxanne Duan

George Komatsoulis

Ping Fan

Victor Piryatinsky

Michael Mucenski

Charles Florence

Hussein Hallak

Moti Rosenstock

Liron Shemesh-Darvish

Daniel P Soppet

Daniel R Bednarik

Jason B Bock

Liora Sklair-Tavron

Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.

De novo binding domain containing polypeptides and uses thereof

Provided herein are D domain containing polypeptides that specifically bind targets of interest, as are nucleic acids encoding the D domain containing polypeptides, vectors containing the nucleic acids and host cells containing the nucleic acids and vectors. Also provided herein are methods of making and using the D domain containing polypeptides, nucleic acids, vectors and host cells, for example, but not limited to, in diagnostic and therapeutic applications. Also provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and Adapters and their use in methods of directing immune responses to target cells. In some embodiments, the methods include the use of a CAR expressing cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or direct CAR expressing cell-mediated immune response in vitro and in vivo.

D-domain containing polypeptides and uses thereof

Provided herein are multi-functional chimeric antigen receptor (CAR)-based compositions and their use in directing immune responses to target cells. The compositions have uses that include treating hyperproliferative disorders such as cancer. The provided methods generally include the use of a CAR cell in combination with an Adapter. The Adapter confers the ability to modulate, alter, and/or redirect CAR cell-mediated immune response in vitro and in vivo. In some embodiments, the CAR cell comprises a genetic modification to reduce or eliminate the expression of a targeted antigenic determinant.

Multifunctional immune cell therapies

Compositions containing multivalent and monovalent multispecific complexes having scaffolds such as antibodies that support such binding functionalities are described. The use of and methods of compositions containing multivalent and monovalent multispecific complexes having scaffolds, such as antibodies, that support such binding functionalities are also described.

Multivalent and monovalent multispecific complexes and their uses

EGFR-binding modular recognition domains (MRDs) and complexes containing such MRDs linked to antibodies are described. The use of such MRDs and complexes are also described.

EGFR-binding modular recognition domains

Complexes containing one or more modular recognition domains (MRDs) and MRDs attached to scaffolds including antibodies are described. The manufacture of these complexes are the use of these complexes to treat and diagnose diseases and disorders are also described.

Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides

Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof

A method of attenuating a biological effect of cocaine exposure in a primate. Such method includes administering to the primate an amount of a BChE-albumin fusion protein comprising the amino acid substitutions A227S, S315G, A356W, and Y360G, wherein the amount of the fusion protein is effective to cause attenuation of the biological effect of cocaine exposure in the primate.

BChE albumin fusions for the treatment of cocaine abuse

The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.

Precerebellin-like protein

94 Human Secreted Proteins

186 human secreted proteins

Growing community of inventors

Washington, DC, United States of America

David William Lafleur